We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

SARTORIUS AG

Sartorius AG is a developer of bioprocess solutions and laboratory products and services that enable pharmaceutical r... read more Featured Products: More products

Download Mobile App




Sartorius Stedim Biotech Partners with Nova Biomedical

By LabMedica International staff writers
Posted on 18 May 2017
Sartorius Stedim Biotech, which supplies products and services to the biopharmaceutical industry, has entered into an agreement with Nova Biomedical, a manufacturer of cell culture analyzers, to integrate their BioProfile FLEX2 into the ambr multi-parallel bioreactor systems for automated, at-line cell culture analytics.

SSB is a total solutions provider with a portfolio covering almost all steps of biopharmaceutical manufacture, and focuses on single-use technologies and value-added services. More...
The ambr systems are designed and manufactured by TAP Biosystems, which is a part of the SSB Group and provides automated cell culture and fermentation systems for life science research, development and production. The ambr platform mimics the characteristics of classical bioreactors at the microscale by allowing automated parallel processing of single-use bioreactors, and is used for cell line development and process optimization by pharmaceutical, biotechnology and academic laboratories.

Nova Biomedical develops and manufactures whole blood, point-of-care and critical care analyzers, as well as provides the biotechnology industry with instruments for cell culture monitoring. The company’s biosensor technology is incorporated in handheld meters for glucose self- and point-of-care testing and critical care whole blood analyzers for rapid measurement of over 20 analytes. Its biotechnology-specific BioProfile line has pioneered comprehensive cell culture testing, providing over 20 critical cell culture tests with over 12 unique instrument offerings for broad range of cell culture applications.

The partnership between SSB and Nova Biomedical will allow both the BioProfile FLEX2 analyzer and the parallel bioprocessing functionality of the ambr to create a unique tool which can simultaneously run, sample and analyze a massive number of cell culture conditions during high-throughput cell line, media and process development by Design of Experiments (DoE). This will allow biopharmaceutical companies to develop well-characterized cell culture processes in less time while preventing the process development bottleneck from being shifted to the analytical laboratory. The integration of ambr and the BioProfile FLEX2 will benefit users by allowing independent sampling, sample transfer, analysis and automated feedback control in each mini bioreactor.

“The combination of ambr and Nova’s BioProfile FLEX2 solution saves time by significantly increasing the amount of data that can be generated per run,” said Stefan Schlack, Senior Vice President Marketing and Product Management at SSB. “Together with our Umetrics and BioPAT MFCS software suites, this will offer a complete solution to generate and analyze the vast amounts of data required for a QbD approach to upstream bioprocess development.”

“We’re very excited about this collaboration. The combination of Nova’s expertise in automated cell culture analysis and Sartorius’ talent in delivering micro-scale smart reactors will yield tremendous benefits for the biotech industry,” said Nicholas Theodore, Senior Vice President of Global Sales for Nova Biomedical. “The integration of BioProfile FLEX2 with the ambr cell culture systems will result in accelerated commercialization of products and the ability to develop more products at lower cost, while ensuring the best quality of biotherapeutics for patients worldwide.”


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Integrated Biochemical & Immunological System
Biolumi CX8
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.